Abbott, a Chicago-based pharmaceutical company, is acquiring Madison-based biotechnology company Exact Sciences, which will become a subsidiary of Abbott, in a $21 billion deal, the companies ...
Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...
Abbott Laboratories ABT0.97%increase; green up pointing triangle agreed to acquire cancer diagnostics company Exact Sciences EXAS-0.03%decrease; red down pointing triangle in a deal valued at about ...
North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...
The acquisition will allow the diagnostics giant to enter the rapidly growing market for cancer tests Exact Sciences sells Cologuard, the at-home test for colorectal cancer that allows some patients ...
The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...
Abbott announced Thursday morning that it is acquiring Exact Sciences for $21 billion. The deal values Exact Sciences at $105 per share, representing a 22% premium to the cancer screening company’s ...
Nov 19 (Reuters) - Medical device maker Abbott Laboratories (ABT.N), opens new tab is nearing a potential takeover of cancer test maker Exact Sciences Corp (EXAS.O), opens new tab, Bloomberg News ...
Bloomberg reports today that Abbott (NYSE: ABT) + is close to a deal to acquire diagnostics developer Exact Sciences (Nasdaq:EXAS). The report cites people familiar with the matter. They reportedly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback